IN VITRO SELECTION OF FUNCTIONALIZED DNA APTAMERS

功能化 DNA 适体的体外选择

• 批准号: 2793594
• 负责人: GIDEON SHAPIRO
• 金额: $ 31.8万
• 依托单位: ERAGEN BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2793594
• 关键词: DNA; DNA directed DNA polymerase; catalyst; chemical binding; enzyme activity; interleukin 1; ligands; oligonucleotides; polynucleotides; receptor; site directed mutagenesis

DESCRIPTION (Applicant's abstract): In vitro selection is a powerful tool for generating new ligands, receptors, and catalysts for targeted receptors, ligands and reactions. In its most commonly used form, in vitro selection begins with libraries of oligonucleotides built from standard bases (A, T, G, and C). The Phase I study demonstrated the feasibility of expanding the functionality of oligonucleotides generated by in vitro selection methods and illustrated how functionalized in vitro selection (FINVIS) yielded products with improved properties in a specific test case. In Phase II, the ability of FINVIS to generate improved ligands, receptors and catalysts will be carefully quantitated and documented. FINVIS will also be used to target two products of medical relevance. Lastly, polymerases that support FINVIS will be further developed by screening and site-directed mutagenesis. The data from Phase II will complete a compelling case for FINVIS against commercial targets, including diagnostic tools, affinity reagents, and therapeutic agents. Commercial partners for Phase III are already being engaged. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（申请人的摘要）：体外选择是一个强大的工具 为目标受体产生新的配体、受体和催化剂， 配体和反应。最常用的形式是体外选择 从由标准碱基（A、T、G、 和C）。第一阶段研究证明了扩大研究范围的可行性 通过体外选择方法产生的寡核苷酸的功能和 说明了功能化体外选择 (FINVIS) 如何产生产品 在特定测试用例中具有改进的性能。在第二阶段，能力 FINVIS 将仔细研究生成改进的配体、受体和催化剂 量化并记录。 FINVIS 还将用于针对以下两种产品 医学相关性。最后，支持 FINVIS 的聚合酶将进一步 通过筛选和定点诱变开发。第二阶段的数据 将为 FINVIS 针对商业目标完成一个令人信服的案例， 包括诊断工具、亲和试剂和治疗剂。 第三阶段的商业合作伙伴已经开始参与。 拟议的商业应用：不可用